BMRN · NASDAQ · Biotechnology
Stock since the trade −14.1% · S&P 500 +1.3% · to Oct 5
BioMarin Pharmaceutical's Chief Legal Officer sold $1.16M of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Stock since the trade +6.3% · S&P 500 +5.9% · to Oct 5
BioMarin Pharmaceutical's Chief R&D Officer sold $177K of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Stock since the trade −4.6% · S&P 500 +14.6% · to Oct 5
BioMarin Pharmaceutical's Chief Technical Officer sold $997K of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Stock since the trade −5.8% · S&P 500 +12.4% · to Oct 5
BioMarin Pharmaceutical's Chief Legal Officer sold $1.6M of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Stock since the trade −5.8% · S&P 500 +12.4% · to Oct 5
BioMarin Pharmaceutical's Chief R&D Officer sold $382K of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
